A small randomized controlled trial found that 1g of daily curcumin for 60 days dramatically reduced IL-17 inflammatory markers in COPD patients compared to placebo. Patients also experienced fewer exacerbations, less coughing, and improved breathing — with benefits lasting up to 6 months post-treatment. Researchers call it a "promising, affordable" anti-inflammatory add-on for a disease that's the third leading cause of death worldwide.
A daily gram of curcumin — the compound that gives turmeric its golden hue — may be a surprisingly powerful tool against COPD inflammation. A triple-blind, randomized, placebo-controlled trial presented at the CHEST 2026 Annual Meeting found that 60 days of curcumin supplementation slashed IL-17 levels by 72% from baseline in COPD patients, while the placebo group saw a 146% increase over the same period. Cough and dyspnea scores also improved significantly in the curcumin group.
Beyond inflammation, the benefits extended to real-world outcomes. Exacerbation rates dropped during treatment and remained lower even 6 months after the trial ended — a notable finding for a disease that kills millions globally each year.
By the Numbers:
Why it matters: COPD is the world's third leading cause of death, and affordable add-on therapies are desperately needed. If these results are replicated in larger, more diverse trials, curcumin — a widely available, low-cost supplement — could become a meaningful part of COPD management.
